Skip to main contentSkip to navigationSkip to search
Curasight
  DKK  % |
Curasight

Annual Report 2025

February 26, 2026

Regulatory

Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand therapy platform  across multiple aggressive solid tumors, hereby publishes the Annual Report 2025. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Curasight’s CEO Ulrich Krasilnikoff comments:

“2025 was a transformative year for Curasight. We transitioned from platform validation to active clinical execution by dosing the first patient in our Phase 1 glioblastoma trial with uTREAT®, marking our evolution into a clinical-stage radiopharmaceutical company. This milestone reflects years of scientific development around our uPAR-targeted RLT platform and positions us with a clear and meaningful catalyst in 2026.

Our therapeutic program is supported by uTRACE®, which has now been evaluated in more than 450 patients and continues to provide a strong human evidence base for our shared uPAR-targeting approach. In parallel, we advanced clinical phase 2 trial in prostate cancer and ensured manufacturing and supply readiness to support ongoing and future development.

As we enter 2026, our focus is clear: disciplined clinical execution, high-quality data generation, and strategic decisions that maximize the long-term value of our uPAR radioligand therapy platform. With a strengthened balance sheet following DKK 63.4 million in equity and DKK 40 million in new and renegotiated debt facilities, we enter 2026 focused on disciplined execution and delivery of key clinical milestones.”

Q1-Q4 (2025-01-01 – 2025-12-31)

  • Gross loss amounted to kDKK -49,676 (kDKK -32,731)
  • Operating loss amounted to kDKK -55,592 (kDKK -40,367)
  • Loss before tax amounted to kDKK -58,730 (kDKK -42,336)
  • Loss for the year amounted to kDKK -53,230 (kDKK -36,836)
  • Total assets amounted to kDKK 50,055 (kDKK 23,688)
  • Equity ratio amounted to 37.1% (32.6%)
  • Earnings per share amounted to DKK -1.1 (DKK -1.74)

Numbers in parenthesis are the numbers from the same period in 2024.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

E-mail: [email protected]

www.curasight.com

Downloads

About Curasight A/S

Curasight is advancing uTREAT®, a clinical-stage, first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat solid tumors. uTREAT® targets uPAR, a key driver of tumor invasion, angiogenesis, and metastasis, which is expressed in more than 85% of solid tumors. The company’s theranostic platform also includes uTRACE®, a uPAR-PET imaging agent built on the same proprietary ligand as uTREAT®. uTRACE® supports patient selection and confirms tumor targeting and has been evaluated in more than 450 patients across nine Phase II trials in eight solid tumor indications. The uPAR platform is based on more than a decade of research at the Copenhagen University Hospital and the University of Copenhagen.